Clicky

Stealth BioTherapeutics Corp.(MITO)

Description: Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in Newton, Massachusetts.


Keywords: Biotechnology Biology Disease Peptides Neurodegenerative Diseases Dysfunction Amyotrophic Lateral Sclerosis Degenerative Disease Neurodegeneration Senescence Oxidative Stress Mitochondria Mitochondrion Mitochondrial Dysfunction

Home Page: www.stealthbt.com

MITO Technical Analysis

190 Elgin Avenue
George Town, KY1-9005
Cayman Islands
Phone: 617-600-6888


Officers

Name Title
Ms. Irene P. McCarthy J.D. Pres ,CEO, Sec. & Director
Mr. Henry Hess Chief Legal Counsel
Dr. Ben R. Bronstein M.D. Chief Medical Officer
Mr. Brian Hotchkiss VP of Bus. Devel. & Strategy

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 36.5663
Price-to-Sales TTM: 3.0313
IPO Date: 2019-02-15
Fiscal Year End: December
Full Time Employees: 38
Back to stocks